Peter Ulrichts

Peter Ulrichts is the Chief Scientific Officer at argenx and joined the company in 2010. In this role, he oversees the development of all clinical and pre-clinical compounds within argenx’s pipeline.

Peter joined the company as a research scientist where he was involved in the development of various therapeutic antibodies for the treatment of cancer and autoimmune diseases. While at argenx, he headed the development of argenx’ FcRn antagonist efgartigimod until the first-in-human study, after which he transitioned to become the lead scientist of the efgartigimod program.

Peter holds a B.S. in Chemistry from KU Leuven as well as an M.S. in Biotechnology and Ph.D. in Immunology, both from the University of Ghent (Belgium).